CR

Chris Reyes

40 years · Merck · former Sr. Director, CMC

Regulatory CMCFailure-mode analysisSponsor strategyEMA / FDA

CR · in his own words

“The decision logic in this industry has been trapped in heads and emails for thirty years. Krux is the first system I've seen that captures it without dumbing it down. We're not making the chemistry easier. We're making the institutional memory finally addressable.”

Background

Chris spent 40 years at Merck across Rahway, NJ and West Point, PA, finishing as Sr. Director of CMC for the small-molecule and peptide portfolio. He led the CMC sections of 14 IND submissions, 6 NDAs, and 3 MAAs across a career spanning four therapeutic areas.

He built Merck's internal failure-mode database in 2008. It was the first attempt inside a top-5 sponsor to systematically codify why CDMO campaigns failed. That program is the conceptual ancestor of the Krux Knowledge Base.

Since retiring in 2025, Chris has been advising two top-20 sponsors on CDMO selection and process-tech transfer. He joined Krux as a founding advisor because, in his words, 'this is the database I tried to build at Merck for ten years and couldn't.'

One save that mattered

Spotted the EMA Q3D shift before it cost the program 9 months.

When the EMA's post-2024 Q&A on parenteral elemental impurities started landing as actual RFIs in 2025, most CMC teams were still writing risk-assessment-only language in their dossiers. Chris flagged the pattern across two Merck programs and one external sponsor program in the same month, escalated it to Quality teams, and got per-element specs added before submission. Three other sponsors got RFIs that quarter on the exact same language; Merck didn't.

→ Saved ~9 months of clinical timeline on a $1.2B-NPV program by avoiding a single round of RFI on parenteral spec language.

4 codified protocols

What Chris taught Krux.

Each protocol below was captured 1-on-1 over interview sessions, validated against batch records, and is now grounding live RFP responses for TCG GreenChem.

kb-a-2Failure mode

Aib failure mode: Merck case file

Two top-10 CDMOs lost peptide batches between 2019–2022 specifically on Aib coupling. Pattern was identical: HBTU/HOBt-only on first run, deletions show up at 4–5% of mass, fail spec. RFI from FDA both times. The fix was already documented internally; the CDMOs didn't have access. Now they do.

captured 2026-03-22 · used in 3 drafts

confidence92%

kb-a-3Regulatory

EMA Q3D enforcement on parenteral biologics

Since post-2024 Q&A guidance, EMA expects per-element specs (Pb, Cd, As, Hg plus Class 2A and key 2B) at parenteral PDE limits, not just a Q3D risk assessment. Three RFIs landed in 2025 on biologics where the dossier had risk-assessment language only.

captured 2026-02-28 · used in 7 drafts

confidence90%

kb-a-5Sponsor intel

Phase 2 biotechs: what they really evaluate

Phase 2 biotech sponsors say price; they actually evaluate timeline reliability and IND-readiness package quality. Win pattern: tightest timeline you can credibly defend in the bid defense, not lowest bid. The tell is whether the sponsor's CMC head pushes back on the Gantt during defense. If they do, you're winning on schedule reliability.

captured 2026-04-09 · used in 6 drafts

confidence86%

kb-a-7Regulatory

PMDA briefing: when to file pre-IND

If the molecule is novel-modality (peptide, oligo, ADC) and the sponsor plans Japanese sites in Phase 3, a pre-IND briefing with PMDA on CMC is worth the 8 weeks. Skip it for small-molecule programs even if Japan is in scope. PMDA's small-mol expectations track FDA closely enough that the briefing rarely surfaces deltas.

captured 2026-04-15 · used in 2 drafts

confidence88%

Try it

See Chris’s protocols flagging an RFP

Open the BX-3142 workspace → look for CR citations →

Other founding advisor

JA

Joe Adams

See codified protocols →